Search Result

Results for "

PET imaging

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) ADC Linkers (2) Amino Acid Derivatives (3) Amino acid Transporter (1) Amyloid-β (5) Apoptosis (3) Arrestin (1) ASCT (1) Bacterial (1) Biochemical Assay Reagents (32) Bombesin Receptor (2) Calcium Channel (1) Cannabinoid Receptor (2) Carbonic Anhydrase (4) Caspase (1) Cholecystokinin Receptor (1) Claudin (1) COX (1) CXCR (3) Cytochrome P450 (2) DNA/RNA Synthesis (1) Dopamine Receptor (2) Drug Derivative (6) Drug Intermediate (9) Drug Metabolite (1) EGFR (4) Epigenetic Reader Domain (1) Estrogen Receptor/ERR (1) Exosomes (1) FAAH (1) FAP (10) Fluorescent Dye (5) Formyl Peptide Receptor (FPR) (1) G-quadruplex (1) Galectin (1) GLUT (1) Glycine Receptor (GlyR) (1) Glycoprotein VI (1) GSK-3 (1) HDAC (2) Histamine Receptor (1) Histone Demethylase (1) hnRNP (2) HSP (2) Integrin (4) Interleukin Related (2) Isotope-Labeled Compounds (2) Ligands for Target Protein for PROTAC (2) mAChR (2) MAGL (1) Melanocortin Receptor (2) Methionine Adenosyltransferase (MAT) (1) mGluR (2) Microtubule/Tubulin (3) Mitochondrial Metabolism (1) MMP (1) MOFs (1) Neurokinin Receptor (2) Neurotensin Receptor (1) P-glycoprotein (1) P2Y Receptor (1) PARP (2) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (1) Potassium Channel (1) Prolyl Endopeptidase (PREP) (1) PSMA (11) Radionuclide-Drug Conjugates (RDCs) (53) Reference Standards (3) RIP kinase (2) ROR (2) Ser/Thr Protease (2) Sigma Receptor (3) Somatostatin Receptor (6) Src (1) Tau Protein (3) TNF Receptor (1) TREM receptor (2) TROP2 (1) TSPO (1) VISTA (1) α-synuclein (2)
By Research Areas:	Cancer (108) Cardiovascular Disease (6) Endocrinology (1) Infection (2) Inflammation/Immunology (12) Metabolic Disease (4) Neurological Disease (44)
Click Chemistry:	BCN (1) Tetrazine (2)

179

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Click Chemistry

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-42110

Deschloroclozapine Maximum Cited Publications 85 Publications Verification	mAChR	Neurological Disease
Deschloroclozapine, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist, with blood-brain barrier permeability. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with K_i of 6.3 and 4.2 nM, respectively. [ ¹¹C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging .

HY-128890

DOTA-NHS-ester 1 Publications Verification	ADC Linkers	Cancer
DOTA-NHS-ester is a linker for affibody molecules and is applied in small animals PET, SPECT, and CT. DOTA-NHS-ester can be used to label radiotherapeutic agents or imaging probes for the detection of tumors .

HY-106244

DOTATATE 4 Publications Verification Oxodotreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-128643

FAPI-4 30+ Cited Publications	FAP	Cancer
FAPI-4 is a potent fibroblast activation protein (FAP) inhibitor for the targeting FAP. FAPI-4 can be used in cancer research. ⁶⁸Ga-FAPI-4 PET/CT is a promising new diagnostic method for imaging various kinds of cancer, with good tumor-to-background contrast ratios .

HY-125399

PSMA-11 1 Publications Verification HBED-CC-PSMA	PSMA Radionuclide-Drug Conjugates (RDCs)	Cancer
PSMA-11 is a small molecule ligand that targets prostate-specific membrane antigen (PSMA) and has the ability to inhibit PSMA activity. PSMA-11 can be used to synthesize ⁶⁸Ga-PSMA-11, a positron emission tomography (PET) tracer that can be used to image advanced prostate cancer .

HY-159181

p-NCS-Bz-DOTA-GA	Biochemical Assay Reagents	Others
p-NCS-Bz-DOTA-GA is a bifunctional chelator. p-NCS-Bz-DOTA-GA can be used as a versatile linker in targeted molecular imaging for both PET/SPECT and MRI applications .

HY-134797

p-SCN-Bn-deferoxamine 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs)	Cancer
P-SCN-Bn-deferoxamine is a bifunctional chelating agent that can link radioactive metal nuclides (such as Zr-89) and biological targeting molecules (such as antibodies). P-SCN-Bn-deferoxamine can be used for the research of immune PET imaging .

HY-42110A

Deschloroclozapine dihydrochloride Maximum Cited Publications 85 Publications Verification	mAChR	Neurological Disease
Deschloroclozapine dihydrochloride, a metabolite of Clozapine, is a highly potent muscarinic DREADDs agonist. Deschloroclozapine binds to DREADD receptor subtypes hM3Dq and hM4Di with K_i of 6.3 and 4.2 nM, respectively. [ ¹¹C]-Deschloroclozapine is developed as a promising PET tracer for DREADD imaging .

HY-120947

AV-105	Drug Intermediate	Neurological Disease
AV-105 is a Florbetapir ( ¹⁸F)-radiolabeled slyrylpyridine tosylate precursor extracted from patent WO2010078370A1, example 1.5. AV-105 can synthesize ¹⁸F-radiolabeled compounds, which are used for positron emission tomography (PET) imaging of neurodegenerative diseases of the brain .

HY-106244A

DOTATATE acetate 4 Publications Verification Oxodotreotide acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-134418

NOTA	Radionuclide-Drug Conjugates (RDCs)	Cardiovascular Disease Cancer
NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research .

HY-W250574

NOTA-bis(tBu)ester NOTA-bis(t-Butyl ester)	Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Drug Derivative	Cancer
NOTA-bis (tBu) ester is a derivative of NOTA (HY-134418). NOTA-bis (tBu) ester is radiolabeled with ⁶⁸Ga to form ZD2-( ⁶⁸Ga-NOTA) after conjugation with ZD2. ZD2-( ⁶⁸Ga-NOTA) can be used for PET imaging studies of pancreatic cancer .

HY-75706

N-Descyclopropanecarbaldehyde Olaparib	PARP Ligands for Target Protein for PROTAC	Cancer
N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 (HY-141481) . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled with F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .

HY-117756

Piflufolastat DCFPYL	PSMA	Cancer
Piflufolastat (DCFPYL) can be used for the preparation of piflufolastat F 18 (DCFPyL F-18). Piflufolastat F-18 (DCFPyL F-18) is an ¹⁸F-labeled imaging agent. Piflufolastat F-18 can be used for positron emission tomography (PET) targeting prostate-specific membrane antigen (PSMA). Piflufolastat can be used for imaging of prostate cancer .

HY-153549

Pentixafor 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-137002

Fmoc-N-Me-Arg(Pbf)-OH	Amino Acid Derivatives Biochemical Assay Reagents	Others
Fmoc-N-Me-Arg(Pbf)-OH is an amino acid derivative containing a guanidinium protecting group on the arginine side chain. Fmoc-N-Me-Arg(Pbf)-OH is used in the synthesis of neurotensin-derived NTS1 ligands for PET imaging .

HY-153248

PBR28	Biochemical Assay Reagents	Neurological Disease Inflammation/Immunology
PBR28 is a translocator protein (TSPO) binding positron emission tomography (PET) radiotracer with blood-brain barrier permeability . PBR28 binds to TSPO, a marker of microglial activation and neuroinflammation, and is used for neuroinflammation imaging in brain diseases and HIV-infected individuals .

HY-19997

Mannose triflate TATM	Biochemical Assay Reagents	Cancer
Mannose triflate is a glucose analog. Mannose triflate is a precursor for 18F-FDG synthesis for PET applications. Mannose triflate binds to 18F via SN2 nucleophilic substitution reaction. Mannose triflate can be used for an imaging technique in detection of cancer .

HY-P2336A

CCZ01048 TFA 4 Publications Verification	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-105252A

BF 227	Amyloid-β	Neurological Disease
BF 227 is a candidate for an amyloid imaging probe for PET, with a K_i of 4.3 nM for Aβ1-42 fibrils.

HY-129650

Florbetapir 1 Publications Verification AV-45; Flobetapir	Biochemical Assay Reagents	Others
Flobetapir (AV-45) may be a well-tolerated imaging agent. Flobetapir synthesizes Florbetapir (18F) that is a PET scanning radiopharmaceutical compound containing the radionuclide fluorine-18 .

HY-P10137

Satoreotide JR11	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
Satoreotide (JR11) is a somatostatin receptor subtype 2 (sstr2)-selective antagonist. Satoreotide can be used as a PET imaging agent when labeled with ⁶⁸Ga. Satoreotide can be used for cancer research .

HY-141729

Biotin-NH-PSMA-617	Fluorescent Dye	Cancer
Biotin-NH-PSMA-617 is a biotin-tagged PSMA-617. PSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA), which is directly expressed by the tumor cells .

HY-137557

Florzolotau APN1607; PM-PBB3	Tau Protein	Neurological Disease
Florzolotau (APN1607) is a positron emission tomography (PET) ligand that can be used for the detection of Alzheimer's disease (AD) and other tau proteinopathies. Its binding sites are located in the β-sheet of paired helical filaments (PHFs) and straight filaments (SFs) of tau protein, as well as in the C-shaped cavity of SFs. In addition, APN-1607 binds to intraneuronal inclusions in Alzheimer's disease (AD), primary age-related tauopathy (PART) and posterior cortical atrophy (PCA). Florzolotau shows promise for PET imaging studies of neurological disorders, particularly tau proteinopathies .

HY-W539893

NODAGA-tris(t-Bu ester) NODAG	Biochemical Assay Reagents	Cancer
NODAGA-tris(t-Bu ester) (NODAG) is a NODAGA derivative. NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-155483

PSMA-BCH NOTA-PSMA	Radionuclide-Drug Conjugates (RDCs)	Cancer
PSMA-BCH (NOTA-PSMA) is a NOTA-conjugated precursor. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools .

HY-100275

MK-3328	Amyloid-β	Neurological Disease
MK-3328 is a β-Amyloid ligand, which exhibits high binding potency with an IC₅₀ of 10.5 nM. MK-3328 is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging .

HY-163574

TDP-43 ligand-1 1 Publications Verification	hnRNP	Neurological Disease
TDP-43 ligand-1 is a specific ligand for TDP43, and its K_i value for binding to TDP-43 protein aggregates is 78 nM. TDP-43 ligand-1 can be used in the research of PET imaging probes for TDP-43 proteinopathies.

HY-128890B

DOTA-NHS-ester TFA 1 Publications Verification	ADC Linkers Biochemical Assay Reagents	Cancer
DOTA-NHS-ester (TFA) is used as a linker for affibody molecules, and it can be employed in small animal positron emission tomography (PET), single photon emission computed tomography (SPECT), and CT scanning. DOTA-NHS-ester can be used to label radiotracers or imaging probes for tumor detection .

HY-177459

DOTA-2P(FAPI)2	FAP	Cancer
DOTA-2P(FAPI)2 is a dimeric FAP (fibroblast activation protein) that can be used as a PET imaging agent and a tracer for tumor therapy .

HY-160607

MMA-NODAGA	Radionuclide-Drug Conjugates (RDCs) Exosomes	Others
MMA-NODAGA is a chelator for site-specific labeling of targeting proteins containing unpaired cysteine. MMA-NODAGA can be used to conjugate with exosome and ⁶⁴Cu in image with positron emission tomography (PET) ^<[2].

HY-175685

FAP-IN-7	FAP	Cancer
FAP-IN-7 (Compound 5b) is a FAPPET imaging and radionuclide therapy of cancers research .

HY-141464

Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH Fmoc-Asn(Ac3AcNH-beta-Glc)-OH	Amino Acid Derivatives	Cancer
Fmoc-L-Asn(beta-D-GlcNAc(Ac)3)-OH (Fmoc-Asn(Ac3AcNH-beta-Glc)-OH) can be used in the synthesis of silicon-fluoride acceptor (SiFA) derivatized octreotate derivatives. SiFA-octreotate analogues, as tumor imaging agents, are useful tool for the research of positron emission tomography (PET) .

HY-P2336

CCZ01048	Melanocortin Receptor	Cancer
CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .

HY-134418R

NOTA (Standard)	Radionuclide-Drug Conjugates (RDCs) Reference Standards	Cardiovascular Disease Cancer
NOTA (Standard) is the analytical standard of NOTA. This product is intended for research and analytical applications. NOTA is a bifunctional chelate which acts as the framework to construct PET imaging tools. NOTA also can be used for probe design and signal amplification via the multivalent effect. NOTA can be used in multiple myeloma, breast cancer, lymphoma and myocardial infarction research .

HY-175730

CB2R ligand-1	Cannabinoid Receptor	Neurological Disease Inflammation/Immunology Cancer
CB2R ligand-1 (Compound L14) is a selective Cannabinoid type 2 receptor (CB2R) ligand with a with K_i of 0.16  nM for CB2R over CB1R. CB2R ligand-1 as be used as a tracer for positron emission tomography (PET) imaging of neurodegenerative diseases, inflammation and cancer .

HY-141804

ER176 BIBD-239	Biochemical Assay Reagents	Neurological Disease
ER176 is a next generation PET radioligand for imaging 18 kDa translocator protein (TSPO), a biomarker for neuroinflammation .

HY-110141

ABP688	mGluR	Others
ABP688 is a high affinity human mGluR5 antagonist with anK_i of 1.7 nM. Radioisotope-labeled ABP688 can be used as a PET tracer for clinical imaging of the mGlu5 receptor .

HY-172205

CHL2310	Cytochrome P450	Cancer
CHL2310 is the inhibitor for CYP46A1 with an IC₅₀ of 0.11 nM, and a K_d of 0.37 nM. CHL2310 can cross blood-brain barrier. CHL2310 can be used as a PET imaging agent, when labeled with radioactive ¹⁸F .

HY-180447

Tz-Ph-PEG4-NH-DOTA	Radionuclide-Drug Conjugates (RDCs)	Cancer
Tz-Ph-PEG4-NH-DOTA (Compound 10) is a 1,2,4,5-tetrazine (Tz) derivative. Tz-Ph-PEG4-NH-DOTA can be used in PET imaging and tumor research .

HY-101182

THK-5117	Microtubule/Tubulin	Neurological Disease
THK-5117, an arylquinoline derivative, displays high binding affinity to tau fibrils with a K_i of 10.5 nM. THK-5117 has high binding affinity to tau protein aggregates and tau-rich Alzheimer disease (AD) brain homogenates. 18F-THK-5117 has the potential to act as a tau imaging PET probe .

HY-179227

HDAC6 ligand-7	HDAC	Neurological Disease
HDAC6 ligand-7 (Compound 16a) is a positron emission tomography (PET) tracer for the deacetylase 6 (HDAC6) enzyme with a K_d value of 1.66 nM. HDAC6 ligand-7 exhibits excellent HDAC6 inhibitory activity, with IC₅₀ values of 2.7 and 3.7 nM for hHDAC6 and mHDAC6, respectively, and has high selectivity for HDAC1/4/7/8. HDAC6 ligand-7 after being radioactively labeled with fluorine-18, [¹⁸F]HDAC6 ligand-7 shows varying degrees of radioactive uptake in PET, which can reflect the specific binding to HDAC6. HDAC6 ligand-7 can be used for the study of HDAC6 imaging .

HY-176834

3-Deoxy-3-fluoro-D-fructose	GLUT	Cancer
3-Deoxy-3-fluoro-D-fructose (Compound 12) is a derivative of 2,5-Anhydro-D-mannitol. 3-Deoxy-3-fluoro-D-fructose is a selective probe of Hexose transporter 5 (GLUT5). 3-Deoxy-3-fluoro-D-fructose inhibits the transport of D-fructose labeled with 14C by GLUT5 with IC₅₀s of 1.16 and 2.37 µM in EMT-6 and MCF-7 cells. 3-Deoxy-3-fluoro-D-fructose can be used for positron emission tomography (PET) imaging of cancers .

HY-164591

THP(Bz)3-NH2	Radionuclide-Drug Conjugates (RDCs)	Cancer
THP(Bz)3-NH2 is a bifunctional chelator that can be conjugated with radionuclides to prepare radionuclide conjugates (RDCs) .

HY-P11257

DOTA-BP1	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [ ⁶⁸Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma .

HY-P11254

DOTA-FAPT	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-FAPT is a novel targeting FAP tracer. DOTA-FAPT can be radiolabeled with gallium-68 and lutetium-177. DOTA-FAPT can be used for PET imaging studies of cancer-associated fibroblasts .

HY-149869

PSMA-IN-3	PSMA	Cancer
PSMA-IN-3 (compound 17) is a novel high-affinity PSMA inhibitor with an IC₅₀ value of 13 nM. PSMA-IN-3 is suitable for developing an ¹⁸F-labeled radioligand for PET imaging of PSMA in prostate cancer .

HY-169868

NOTA-FAPI-52	Biochemical Assay Reagents	Cancer
NOTA-FAPI-52 is a tracer with potent tumor uptake. NOTA-FAPI-52 can be radiolabeled to enable PET imaging or other bioimaging techniques. NOTA-FAPI-52 can be used to study diseases in which fibroblast activation protein (FAP) is overexpressed .

HY-164475

PARP1-IN-29	PARP	Cancer
PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC₅₀ value of 6.3 nM. PARP1-IN-29, after being labeled with [18F], can be used for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. PARP1-IN-29 is applicable in the fields of oncology and imaging research, particularly for detecting PARP-1 activity in cancer .

HY-174977

P2Y12R ligand-1	P2Y Receptor	Neurological Disease
P2Y12R ligand-1 (Compound 41) is a high-affinity P2Y₁₂R ligand with a K_i value of 17.1 nM. P2Y12R ligand-1 labeled with [ ¹⁸F] can be used in studies of brain PET imaging .

Cat. No.	Product Name	Type

HY-W087187G

DOTAGA-anhydride

Fluorescent Dyes

DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

HY-D2343

PB0822	Fluorescent Dyes
PB0822 can be used for in vivo PET imaging when labeled with [ ¹⁸F]fluoride. [ ¹⁸F]PB0822 is a PET radioligand. [ ¹⁸F]PB0822 has a cLogP value of 1.54, which is a good predictive index for BBB penetration. [ ¹⁸F]PB0822 can be used for Alzheimer’s Disease research .

HY-D2334

AlF-NOTA-c-d-VAP	Fluorescent Dyes
AlF-NOTA-c-d-VAP is a peptide positron emission tomography (PET) probe that used for targeted tumor imaging of GRP78. AlF-NOTA-c-d-VAP demonstrates high stability in vitro and in vivo .

HY-D2310

CXCR2 Probe 1	Fluorescent Dyes
CXCR2 Probe 1 (Compound ^[18F]16b) is a selective ligand for CXCR2 and is a radiotracer for PET imaging of neutrophils in inflammatory diseases .

HY-D3189

5GluAF-2MeTG

Fluorescent Dyes

5GluAF-2MeTG is an activatable fluorescent probe targeting the glutamate carboxypeptidase (CP) activity of PSMA (Ex/Em=490/500-600 nm). After being hydrolyzed by PSMA, 5GluAF-2MeTG releases a cell membrane-permeable fluorescent product, and achieves fluorescence activation by disrupting donor-excited photoinduced electron transfer (d-PeT). 5GluAF-2MeTG enables fluorescence imaging of live PSMA-expressing prostate cancer cells in vitro and visualizes the carboxypeptidase activity of PSMA. 5GluAF-2MeTG can be used to detect prostate cancer regions in preclinical excised tissue specimens .

HY-D3174

PiF

Fluorescent Dyes

PiF is a fluorescent probe with high specificity for pancreatic β-cells (Ex/Em = 535 nm/565 nm), and its fluorescence signal increases significantly with elevated insulin concentrations in in vitro experiments. PiF enables visualization of rat and human islets transplanted via the portal vein in mouse livers with low liver background signals. The fluorine atom of PiF can be replaced by radioactive ¹⁸F to prepare a PET tracer. PiF can be used for research on type 1 diabetes .

Cat. No.	Product Name	Type

HY-159181

p-NCS-Bz-DOTA-GA	Biochemical Assay Reagents
p-NCS-Bz-DOTA-GA is a bifunctional chelator. p-NCS-Bz-DOTA-GA can be used as a versatile linker in targeted molecular imaging for both PET/SPECT and MRI applications .

HY-141637

2-Deoxy-2-fluoro-D-glucose 2 Publications Verification 2-Fluoro-2-deoxy-D-glucose; 2-Deoxy-2-fluoro-D-glucopyranose; Fluorodeoxyglucose	Biochemical Assay Reagents
2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

HY-W250574

NOTA-bis(tBu)ester NOTA-bis(t-Butyl ester)	Biochemical Assay Reagents
NOTA-bis (tBu) ester is a derivative of NOTA (HY-134418). NOTA-bis (tBu) ester is radiolabeled with ⁶⁸Ga to form ZD2-( ⁶⁸Ga-NOTA) after conjugation with ZD2. ZD2-( ⁶⁸Ga-NOTA) can be used for PET imaging studies of pancreatic cancer .

HY-19997

Mannose triflate TATM	Biochemical Assay Reagents
Mannose triflate is a glucose analog. Mannose triflate is a precursor for 18F-FDG synthesis for PET applications. Mannose triflate binds to 18F via SN2 nucleophilic substitution reaction. Mannose triflate can be used for an imaging technique in detection of cancer .

HY-W539893

NODAGA-tris(t-Bu ester) NODAG	Biochemical Assay Reagents
NODAGA-tris(t-Bu ester) (NODAG) is a NODAGA derivative. NODAGA-tris(t-Bu ester) can be used to label peptides, antibodies, etc., and subsequently radiolabeled for PET imaging .

HY-W130177

Iodocholine iodide	Biochemical Assay Reagents
Iodocholine iodide is a non-toxic, metabolizable "green" catalyst that can catalyze the free radical polymerization of functional polymers. Iodocholine iodide is also the non-radioactive iodide of Carbon-11 choline. C-11 Choline can be used in PET imaging and non-informative bone scintigraphy, CT or MRI to monitor various types of cancer .

HY-W087187G

DOTAGA-anhydride

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-106244

DOTATATE 4 Publications Verification Oxodotreotide	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10136

IA9 2 Publications Verification human TREM-2 182-190	TREM receptor	Inflammation/Immunology
IA9 (human TREM-2 182-190) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 can be used for neuroinflammation PET imaging. IA9 can be used for Rheumatoid arthritis (RA) and neuroinflammation research .

HY-P10761

DPI-4452	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC₅₀ for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106244A

DOTATATE acetate 4 Publications Verification Oxodotreotide acetate	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-20167A

H-Glu(OtBu)-OtBu hydrochloride	Neurokinin Receptor	Cancer
H-Glu(OtBu)-OtBu hydrochloride is a key intermediate that can be used to synthesize prostate-specific membrane antigen (PSMA) targeting probes. H-Glu(OtBu)-OtBu hydrochloride can reduce nonspecific background binding through negatively charged linkers, improve tumor/background contrast, and can be used in prostate cancer PET/SPECT imaging studies .

HY-153549

Pentixafor 2 Publications Verification	Radionuclide-Drug Conjugates (RDCs) CXCR	Others
Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with ⁶⁸Gallium ( ⁶⁸Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-137002

Fmoc-N-Me-Arg(Pbf)-OH	Amino Acid Derivatives Biochemical Assay Reagents	Others
Fmoc-N-Me-Arg(Pbf)-OH is an amino acid derivative containing a guanidinium protecting group on the arginine side chain. Fmoc-N-Me-Arg(Pbf)-OH is used in the synthesis of neurotensin-derived NTS1 ligands for PET imaging .

HY-D2363

DOTA.SA.FAPi TFA	Radionuclide-Drug Conjugates (RDCs) FAP Prolyl Endopeptidase (PREP)	Cancer
DOTA.SA.FAPi TFA is a selective FAP inhibitor with an IC₅₀ value of 0.9 nM against FAP. DOTA.SA.FAPi TFA forms stable complexes with ⁶⁸Ga and serves as a PET radiotracer for preclinical imaging of FAP-expressing tumors. DOTA.SA.FAPi TFA can be used in the research of colorectal adenocarcinoma and various other cancers .

HY-P5362

NODAGA-LM3	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Neurological Disease Cancer
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 can serve as a *PET* imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P11287A

DOTA-Pep-1L TFA	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research .

HY-P2336A

CCZ01048 TFA 4 Publications Verification	Melanocortin Receptor	Cancer
CCZ01048 TFA, a α-MSH analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 TFA shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 TFA is a promising candidate for PET imaging of malignant melanoma .

HY-P10137

Satoreotide JR11	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
Satoreotide (JR11) is a somatostatin receptor subtype 2 (sstr2)-selective antagonist. Satoreotide can be used as a PET imaging agent when labeled with ⁶⁸Ga. Satoreotide can be used for cancer research .

HY-P5018

NOTA-AE105	Radionuclide-Drug Conjugates (RDCs) Ser/Thr Protease	Cancer
NOTA-AE105 is a PET ligand for the urokinase-type plasminogen activator receptor (uPAR). NOTA-AE105 can be radiolabeled with ⁶⁴Cu and ⁶⁸Ga. Images of 68Ga-NOTA-AE105 and 64Cu-NOTA-AE105 demonstrate high contrast and clear tumor delineation. NOTA-AE105 can be used in the synthesis of radionuclide-conjugated compounds (RDCs) .

HY-P10136A

IA9 TFA 2 Publications Verification human TREM-2 182-190 TFA	TREM receptor	Inflammation/Immunology
IA9 TFA (human TREM-2 182-190 TFA) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 TFA can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 TFA can be used for neuroinflammation PET imaging. IA9 TFA can be used for Rheumatoid arthritis (RA) and neuroinflammation research .

HY-P10896

NOTA-P2-RM26	Bombesin Receptor	Cancer
NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with ¹¹¹In and ⁶⁸Ga for prostate cancer imaging studies using PET and SPECT/CT .

HY-P5292A

HYNIC-iPSMA TFA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P5413

[Lys3]-Bombesin	Cholecystokinin Receptor	Others
[Lys3]-Bombesin is a biological active peptide. (PET (Positron Emission Tomography) imaging of [Lys3]-bombesin is able to detect gastrin-releasing peptide receptor (GRPR) positive prostate cancer. An immunoconjugate of [Lys3]-bombesin and corresponding monoclonal antibody can specifically induce (CD64)-dependent monocyte and neutrophil-mediated lysis of small cell carcinoma.)

HY-P11287

DOTA-Pep-1L	Interleukin Related Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-Pep-1L is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L yields the isotopically labeled product [ ²²⁵Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L can be used for PET imaging, tumor targeting and glioma research .

HY-P2336

CCZ01048	Melanocortin Receptor	Cancer
CCZ01048, a α-melanocyte-stimulating hormone (α-MSH) analogue, exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a K_i of 0.31 nM. CCZ01048 shows rapid internalization into B16F10 melanoma cells and high in vivo stability. CCZ01048 is a promising candidate for PET imaging of malignant melanoma .

HY-P5292

HYNIC-iPSMA	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11257

DOTA-BP1	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-BP1 is a DOTA-modified BP1 (BCMA-targeting peptide). DOTA-BP1 can be radiolabeled with [ ⁶⁸Ga]Ga to produce a BCMA-targeting PET tracer. DOTA-BP1 can be used in the research of detecting BCMA in multiple myeloma .

HY-P11254

DOTA-FAPT	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-FAPT is a novel targeting FAP tracer. DOTA-FAPT can be radiolabeled with gallium-68 and lutetium-177. DOTA-FAPT can be used for PET imaging studies of cancer-associated fibroblasts .

HY-P10307

DOTA-ubiquicidin (29–41)	Radionuclide-Drug Conjugates (RDCs) Bacterial	Infection
DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ ⁶⁸Ga]Ga-DOTA-Ubiquicidin_29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11253

DOTA-Bn-CA-170	VISTA	Inflammation/Immunology
DOTA-Bn-CA-170 is a molecular probe targeting the VISTA protein, with a K_d value of 0.124 nM. DOTA-Bn-CA-170 is formed by covalently linking the p-SCN-Bn-DOTA ligand with CA-170 (HY-101093). DOTA-Bn-CA-170 labeled with [ ⁶⁸Ga]Ga successfully achieves specific and high-contrast PET imaging of VISTA expression in various tumor-bearing mouse models. DOTA-Bn-CA-170 can be used for the study of VISTA-targeted immunotherapy .

HY-P5362A

NODAGA-LM3 TFA	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC₅₀ = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. ⁶⁸Ga-labeled NODAGA-LM3 TFA can serve as a *PET* imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .

HY-P10744

BQ7859	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P11718

cFLFLF	Formyl Peptide Receptor (FPR) Radionuclide-Drug Conjugates (RDCs)	Inflammation/Immunology
cFLFLF is a FPR-specific peptide. cFLFLF is sequentially conjugated with a bifunctional polyethylene glycol moiety (PEG, 3.4 kD) and a DOTA through a lysine (K) spacer and finally labeled with ⁶⁴Cu-CuCl₂ to form cFLFLFKPEG- ⁶⁴Cu. cFLFLFKPEG- ⁶⁴Cu is a neutrophil-specific PET imaging agent .

HY-P11837

NECT-224	Biochemical Assay Reagents	Cancer
NECT-224 is a bifunctional chelator and a nectin-4 targeting peptide conjugate. NECT-224 can be used as a PET imaging agent when labeled with ⁶⁴Cu or ⁶⁸Ga .

HY-P11655

NOTA-TATE	Somatostatin Receptor	Neurological Disease
NOTA-TATE is a somatostatin receptor 2 (SSTR2) binder. NOTA-TATE binds to SSTR2 to enable targeting of SSTR2-positive tumour cells for PET imaging. NOTA-TATE can be used for the research of neuroendocrine tumours .

HY-P0036D

NOTA-Octreotide	Drug Derivative Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Apoptosis	Cancer
NOTA‑Octreotide is a selective SSTR2‑targeting PET tracer. NOTA‑Octreotide binds specifically to SSTR2 and accumulates in SSTR2‑expressing tissues. NOTA‑Octreotide enables effective imaging of somatostatin receptor‑positive tumors in mice and shows high specific uptake in SSTR2‑expressing organs in healthy rats. NOTA-Octreotide can be used for PET imaging investigation of neuroendocrine tumors. .

HY-P11871

NOTA-GZP	Caspase	Cancer
NOTA-GZP is a high-affinity, specific granzyme B-targeted irreversible inhibitory peptide PET imaging probe. NOTA-GZP can be used for the research of colon carcinoma, melanoma .

HY-P11598

PSMA-N5	PSMA	Cancer
PSMA-N5 (Compound 15) is a PSMA ligand with a K_i value of 0.71 nM. PSMA-N5 acts as a PET radiotracer for prostate cancer imaging. PSMA-N5 is applicable to the research of prostate cancer and other related cancers .

HY-P11816

DOTA-cTMTP1	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-cTMTP1 is a cyclic tumor-homing peptide precursor molecule. DOTA-cTMTP1 selectively binds to XPNPEP2 on highly metastatic tumor cells, accumulates and retains in hepatocellular carcinoma tumors, and maintains a high tumor-to-liver contrast over time in small animal models. After radiolabeling with ⁶⁸Ga, DOTA-cTMTP1 forms a PET probe for positron emission tomography (PET) imaging of hepatocellular carcinoma (HCC).

HY-P11785

Cpe30 MT2	Claudin	Cancer
Cpe30 MT2 is a short peptide that binds tightly junction protein Claudin‑4 (CLDN4) with high affinity, with a K_d value of 1.97 nM. Cpe30 MT2 can be used for the synthesis of PET molecular imaging probes targeting pancreatic cancer .

HY-179583

FSC(PEG4-αvβ6)₃	Integrin	Cancer
FSC(PEG4-avb6)₃ is a tracer targeting αvβ6 integrin trimer (IC₅₀ = 0.69 nM). FSC(PEG4-avb6)₃ can be used for the study of head-and-neck, lung, breast, and pancreatic carcinomas .

HY-P11835

Granzyme B contrast agent-1	Ser/Thr Protease Radionuclide-Drug Conjugates (RDCs)	Others
Granzyme B contrast agent-1 is a Granzyme B binder with a K_d value of 1.0 nM. When radiolabeled, Granzyme B contrast agent-1 can be used for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging studies of Granzyme B .

HY-P11613

DOTA-WC8	EGFR	Cancer
DOTA-WC8 is a HER2-targeting peptide probe with a K_D of 61.20 nM. ⁶⁸Ga-labeled DOTA-WC8 serves as a PET imaging agent for the specific identification of HER2-positive breast cancer. DOTA-WC8 is applicable to breast cancer-related research .

HY-P11596

NOTA-Asp2-αvβ6L	Integrin	Cancer
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .

HY-P11576

Cyclic αvβ6	Integrin Radionuclide-Drug Conjugates (RDCs)	Cancer
Cyclic αvβ6 (Compound c(FRGDLAFp(NMe)K)) is a αvβ6-integrin-specific cyclic nonapeptide. Cyclic αvβ6 can be coupled with ⁶⁸Ga-labeled monomeric triazacyclononane-triphosphinate (TRAP). Cyclic αvβ6 can be used in PET imaging studies for cancers including head and neck cancer and pancreatic cancer .

HY-P11845

DOTA-NT-20.3-IPBA	Radionuclide-Drug Conjugates (RDCs) Neurotensin Receptor	Cancer
DOTA-NT-20.3-IPBA is a Neurotensin receptor 1 (NTR1)-targeting albumin binder with specific high-affinity binding to NTR1. DOTA-NT-20.3-IPBA is formed by the conjugation of DOTA-NT-20.3 and IPBA. DOTA-NT-20.3-IPBA can be used for positron emission tomography (PET) imaging following labeling with [ ⁶⁸Ga]Ga .

HY-P11859

NP1	ROR Radionuclide-Drug Conjugates (RDCs)	Cancer
NP1 is a NOTA-chelated linear precursor based on the ROR1-targeting peptide. After labeling with [ ¹⁸F]AlF, NP1 yields [ ¹⁸F]AlF-NP1, a PET imaging probe with excellent ROR1 specificity (K_D = 141.7 nM), rapid tumor uptake and high target-to-background ratio, which is suitable for non-invasive visualization of various ROR1-overexpressing tumors .

HY-P11858

DP1 peptide	ROR Radionuclide-Drug Conjugates (RDCs)	Cancer
DP1 peptide is a high-affinity ROR1-binding peptide with a K_d value of 74.9 nM. When labeled with ⁶⁸Ga, DP1 peptide serves as a PET imaging agent, which features rapid tumor uptake, favorable target-to-nontarget ratios in various tumor models, and renal clearance, enabling non-invasive quantitative visualization of ROR1 expression. DP1 peptide can be used in research related to melanoma, hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer .

HY-P11590

WGYRGFYC	EGFR	Cancer
WGYRGFYC (WC8) is a selective HER2-targeting peptide that binds specifically to HER2 by mimicking the antigen-binding site of trastuzumab. The DOTA precursor of WGYRGFYC has a K_D of 61.20 nM for HER2. WGYRGFYC enables specific and highly sensitive detection of HER2 expression in HER2-positive breast cancer cells and tumor tissues, and monitors the dynamic downregulation of HER2 expression. WGYRGFYC rapidly distributes to target tissues and is efficiently cleared from non-target tissues via the kidneys, generating an ideal tumor-to-background ratio in imaging; it is a component of the PET radiotracer Ga-DOTA-WC8. WGYRGFYC exhibits no significant cytotoxicity in breast cancer cells, and can be used for non-invasive imaging diagnosis and therapeutic efficacy evaluation of HER2-positive breast cancer .

HY-P11618

10P3Me	Glycoprotein VI	Cancer
10P3Me is a Glypican-3 (GPC3)-targeting probe with a K_a of 93.8 nM for the human target. 10P3Me exhibits high binding affinity to GPC3, targets GPC3-positive cells, and serves as an agent for *PET* imaging. 10P3Me selectively accumulates in GPC3-positive tumor tissues, including subcutaneous xenograft models and orthotopic HepG2-LUC liver cancer models, to achieve precise localization of lesions .

HY-P11737

IPM-N001	Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase	Cancer
IPM-N001 is a carbonic anhydrase IX (CAIX) ligand with a K_d value of <0.0337 nM for hCAIX. When radio-conjugated with ⁶⁸Ga, IPM-N001 serves as a CAIX-targeted radionuclide tracer. [ ⁶⁸Ga]Ga-IPM-N001 exhibits excellent tumor uptake and significantly improves the tumor-to-background ratio in PET/CT imaging studies using OS-RC-2 tumor-bearing mice. IPM-N001 can be used for the research of clear cell renal cell carcinoma .

HY-P11486

NOTA-RHAU18	Radionuclide-Drug Conjugates (RDCs) G-quadruplex DNA/RNA Synthesis Mitochondrial Metabolism	Cancer
NOTA-RHAU18 is a conjugate of the chelator NOTA and the peptide RHAU18. NOTA-RHAU18 can be used to synthesize the radiolabeled peptide probe [ ¹⁸F]AlF-NOTA-RHAU18. [ ¹⁸F]AlF-NOTA-RHAU18 targets mitochondrial DNA G4. [ ¹⁸F]AlF-NOTA-RHAU18 can be used to visualize and detect solid tumors in homozygous mice. [ ¹⁸F]AlF-NOTA-RHAU18 can also be used in PET imaging studies .

Cat. No.	Product Name	Target	Research Area	Image

HY-P992367

hIMB1636	TROP2	Cancer
hIMB1636 is a humanized monoclonal antibody targeting Trop2. By binding to the conformational Trop2 epitope, hIMB1636 regulates related signaling pathways, triggers lysosomal endocytosis, and further induces apoptosis, cell cycle arrest, and antibody-dependent cellular cytotoxicity. hIMB1636 effectively inhibits tumor cell proliferation, migration and in vivo tumor growth, and also exerts bystander killing effect and mediates long-term retention. hIMB1636 can be conjugated with NOTA/DOTA for radiolabeling to enable immuno-PET imaging, or prepared as hIMB1636-LDP-AE to significantly inhibit the growth of breast cancer and lung cancer xenografts .

HY-P992340

CTB006	Radionuclide-Drug Conjugates (RDCs) TNF Receptor	Cancer
CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. ¹⁷⁷Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while ⁸⁹Zr- or ¹⁷⁷Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .

HY-P992341

D8P1C1	MMP	Cancer
D8P1C1 is a high-affinity ADAM17 inhibitor (with a K_d of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. ⁸⁹Zr-DFO-D8P1C1 radioimmunological *PET* imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer .

Cat. No.	Product Name	Chemical Structure

HY-141637S

2-Deoxy-2-fluoro-D-glucose-13C

2-Deoxy-2-fluoro-D-glucose- ¹³C is the ¹³C labeled 2-Deoxy-2-fluoro-D-glucose (HY-141637). 2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

HY-141637S1

2-Deoxy-2-fluoro-D-glucose-13C6,d7

2-Deoxy-2-fluoro-D-glucose- ¹³C₆,d₇ is the ¹³C-labeled and deuterium labeled 2-Deoxy-2-fluoro-D-glucose (HY-141637). 2-Deoxy-2-fluoro-D-glucose (2-Fluoro-2-deoxy-D-glucose) is a glucose analog that can be absorbed by cells. 2-Deoxy-2-fluoro-D-glucose is capable of being labelled with ¹⁸F for positron emission tomography (PET) imaging. ¹⁸F-2-Deoxy-2-fluoro-D-glucose can be used to detect breast cancer and gastric cancer .

Cat. No.	Product Name		Classification

HY-180447

Tz-Ph-PEG4-NH-DOTA		Tetrazine
Tz-Ph-PEG4-NH-DOTA (Compound 10) is a 1,2,4,5-tetrazine (Tz) derivative. Tz-Ph-PEG4-NH-DOTA can be used in PET imaging and tumor research .

HY-170749

DFO-BCN		BCN
DFO-BCN is a drug intermediate, that can be used for synthesis of PET/CT imaging agent DFO-CPC634 through click chemistry .

HY-W422109

4-(6-Methyl-1,2,4,5-tetrazin-3-yl)benzoic acid		Tetrazine
4-(6-Methyl-1,2,4,5-tetrazin-3-yl) benzoic acid is an asymmetric tetrazine derivative and a bioorthogonal reaction partner. 4-(6-Methyl-1,2,4,5-tetrazin-3-yl) benzoic acid can be conjugated with Bevacizumab (HY-P9906) via EDC/NHS activation while retaining the VEGF-binding affinity of the antibody, thus constructing a targeting agent for pretargeted immuno-PET/NIRF imaging .

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W087187G

DOTAGA-anhydride	Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTAGA-anhydride (GMP) is DOTAGA-anhydride (HY-W087187) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride has been successfully used for labeling antibodies (e.g., Trastuzumab (HY-P9907)). DOTAGA-anhydride can be used for the synthesis of a bimodal tag for Single-photon emission computed tomography (SPECT) or PET/optical imaging .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: